Travere Therapeutics (TVTX) Consolidated Net Income (2011 - 2026)

Travere Therapeutics (TVTX) has 16 years of Consolidated Net Income data on file, last reported at -$500000.0 in Q1 2026.

• Quarterly Consolidated Net Income changed N/A year-over-year to -$500000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.2 million (up 3013.96% YoY) and the FY2025 annual result came in at $24.7 million, up 2801.09% from the prior year.
• Consolidated Net Income retreated to -$500000.0 in Q1 2026, from $24.7 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $240.0 million in Q3 2023 to a low of -$1.6 million in Q4 2023.
• A 5-year average of $24.4 million and a median of $8.0 million in 2022 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2023 — Consolidated Net Income plunged 107.96% — and 2025, when it soared 164866.67%.
• Tracing TVTX's Consolidated Net Income over 5 years: stood at $19.8 million in 2022, then plunged by 107.96% to -$1.6 million in 2023, then jumped by 99.05% to -$15000.0 in 2024, then soared by 164866.67% to $24.7 million in 2025, then tumbled by 102.02% to -$500000.0 in 2026.
• The last three Consolidated Net Income figures came in at -$500000.0 (Q1 2026), $24.7 million (Q4 2025), and -$15000.0 (Q4 2024), per Business Quant data.